Home » Stocks » PMVP

PMV Pharmaceuticals, Inc. (PMVP)

Stock Price: $42.33 USD -2.13 (-4.79%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 1.99B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 6.02M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $42.33
Previous Close $44.46
Change ($) -2.13
Change (%) -4.79%
Day's Open 44.23
Day's Range 41.66 - 45.15
Day's Volume 56,338
52-Week Range 31.86 - 61.51

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 5 days ago

There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they believe they can profit remarkably from their investments after the market has...

Other stocks mentioned: AKUS, TARA
GlobeNewsWire - 2 months ago

CRANBURY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnos...

GlobeNewsWire - 2 months ago

CRANBURY, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnos...

GlobeNewsWire - 2 months ago

CRANBURY, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnos...

GuruFocus - 3 months ago

Andreas Halvorsen (Trades, Portfolio) revealed he established a new position in PMV Pharmaceuticals Inc. (NASDAQ:PMVP) on Sept. 25, according to GuruFocus' Real-Time Picks.

GlobeNewsWire - 3 months ago

CRANBURY, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapie...

Seeking Alpha - 3 months ago

U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week

Other stocks mentioned: AMST, BSY, CRSR, FCACU, GDRX, GLSI, GRAY, LSF, PRLD, ARRY
Market Watch - 4 months ago

PMV Pharmaceuticals Inc.'s stock debuted with a bang Friday, as the the stock opened at nearly double the initial public offering price. The first trade was at $35.00 at 12:09 p.m.

Market Watch - 4 months ago

PMV Pharmaceuticals Inc.'s PMVP, initial public offering priced at $18 a share, which was at the top of the expected range of $16 to $18 a share. The oncology compa...

GlobeNewsWire - 4 months ago

CRANBURY, N.J., Sept. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapie...

About PMVP

PMV Pharmaceuticals, a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. Its lead product candidate is PC14586, a small molecule that corrects and restores p53 function. The company also develops product candidates for p53 R273H hotspot mutation and other p53 hotspot mutations. PMV Pharmaceuticals, Inc. was formerly known as PJ Pharmaceuticals, Inc. and changed to in July 2013. The company was founded in 2013 and is headquartered in Cranbury, New Jersey.

Industry
Biotechnology
IPO Date
Sep 25, 2020
CEO
Dr. David H. Mack
Employees
39
Stock Exchange
NASDAQ
Ticker Symbol
PMVP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for PMVP stock is "Buy." The 12-month stock price forecast is 61.33, which is an increase of 44.89% from the latest price.

Price Target
$61.33
(44.89% upside)
Analyst Consensus: Buy